Aegis Medical Innovations

Aegis Medical Innovations

Vancouver, BC, Canada
Express Interest
Aegis has developed a surgically implanted device that reduces the risk of stroke in patients suffering from irregular heartbeat by preventing the flow of blood between the heart and left atrial appendage on the left side of the heart. The surgically implanted device, called Sierra, has been in development for 11+ years with over $15 million invested. The FDA empanelled a group of experts, who after detailed study advised they did not find a single opportunity for improvement. Aegis wishes to undertake a 50-60 patient trial - take 12-18 months, cost $3.5mm, with objective to earn a CE Mark approval for commercial sale of Sierra in Europe. There is a natural pool of buyers for Aegis/Sierra on grant of CE Mark. The precedent transaction is Boston Scientific's purchase of Atritech and its Watchman device, for an up front payment of $100mm and milestone payments of $275mm, 12+ years ago. Their 2022 revenue from their Watchman franchise has eclipsed $1 Billion.. Abbott Laboratories acquired their Amulet device as part of their St. Jude Medical purchase in 2017, with FDA approval granted in 2021. Johnson and Johnson acquired their Wavecrest device in 2015 and Atricure Inc. purchased their Lariat device in 2019. All were first CE Mark approved, prior to initial commercial market entry. Besides being a better, cheaper, faster, safer device, Sierra has two distinct advantages. due to Sierra's epicardial deployment (as opposed to endocardial deployment.) . In about 15% of the patients Sierra, also cures A-Fib and can potentially be a very effective treatment for hypertension. Sierra, atrial fibrillation ("SierraAF") and hypertension ("SierraHT") present the potential opportunity to, at some point, split Aegis into two companies. Low risk is i) the conclusions reached in the FDA review, ii) same doctor that ran Aegis successful 7 patient trial 3 years ago will run our planned 50-60 person triaI iii) Aegis is navigating familiar waters, iv) Boston Scientific and other majors have proven the efficacy, demand, profitability, market, and the procedure is now health insurance supported in many cases. Investor Q&A calls: Twice daily (10am & 4pm PST) Monday-Friday/Robert > Call 1-727-731-5165

Aegis has developed a surgically implanted device that reduces the risk of stroke in patients suffering from irregular heartbeat by preventing the flow of blood between the heart and left atrial appendage on the left side of the heart. The surgically implanted device, called Sierra, has been in development for 11+ years with over $15 million invested. The FDA empanelled a group of experts, who after detailed study advised they did not find a single opportunity for improvement. Aegis wishes to undertake a 50-60 patient trial - take 12-18 months, cost $3.5mm, with objective to earn a CE Mark approval for commercial sale of Sierra in Europe. There is a natural pool of buyers for Aegis/Sierra on grant of CE Mark. The precedent transaction is Boston Scientific's purchase of Atritech and its Watchman device, for an up front payment of $100mm and milestone payments of $275mm, 12+ years ago. Their 2022 revenue from their Watchman franchise has eclipsed $1 Billion.. Abbott Laboratories acquired their Amulet device as part of their St. Jude Medical purchase in 2017, with FDA approval granted in 2021. Johnson and Johnson acquired their Wavecrest device in 2015 and Atricure Inc. purchased their Lariat device in 2019. All were first CE Mark approved, prior to initial commercial market entry. Besides being a better, cheaper, faster, safer device, Sierra has two distinct advantages. due to Sierra's epicardial deployment (as opposed to endocardial deployment.) . In about 15% of the patients Sierra, also cures A-Fib and can potentially be a very effective treatment for hypertension. Sierra, atrial fibrillation ("SierraAF") and hypertension ("SierraHT") present the potential opportunity to, at some point, split Aegis into two companies. Low risk is i) the conclusions reached in the FDA review, ii) same doctor that ran Aegis successful 7 patient trial 3 years ago will run our planned 50-60 person triaI iii) Aegis is navigating familiar waters, iv) Boston Scientific and other majors have proven the efficacy, demand, profitability, market, and the procedure is now health insurance supported in many cases. Investor Q&A calls: Twice daily (10am & 4pm PST) Monday-Friday/Robert > Call 1-727-731-5165

Company Overview

Aegis has developed a surgically implanted device that reduces the risk of stroke in patients suffering from irregular heartbeat by preventing the flow of blood between the heart and left atrial appendage on the left side of the heart.

The surgically implanted device, called Sierra, has been in development for 11+ years with over $15 million invested. The FDA empanelled a group of experts, who after detailed study advised they did not find a single opportunity for improvement. Aegis wishes to undertake a 50-60 patient trial - take 12-18 months, cost $3.5mm, with objective to earn a CE Mark approval for commercial sale of Sierra in Europe.

There is a natural pool of buyers for Aegis/Sierra on grant of CE Mark. The precedent transaction is Boston Scientific's purchase of Atritech and its Watchman device, for an up front payment of $100mm and milestone payments of $275mm, 12+ years ago. Their 2022 revenue from their Watchman franchise has eclipsed $1 Billion.. Abbott Laboratories acquired their Amulet device as part of their St. Jude Medical purchase in 2017, with FDA approval granted in 2021. Johnson and Johnson acquired their Wavecrest device in 2015 and Atricure Inc. purchased their Lariat device in 2019. All were first CE Mark approved, prior to initial commercial market entry.

Besides being a better, cheaper, faster, safer device, Sierra has two distinct advantages. due to Sierra's epicardial deployment (as opposed to endocardial deployment.) . In about 15% of the patients Sierra, also cures A-Fib and can potentially be a very effective treatment for hypertension. Sierra, atrial fibrillation ("SierraAF") and hypertension ("SierraHT") present the potential opportunity to, at some point, split Aegis into two companies.

Low risk is i) the conclusions reached in the FDA review, ii) same doctor that ran Aegis successful 7 patient trial 3 years ago will run our planned 50-60 person triaI iii) Aegis is navigating familiar waters, iv) Boston Scientific and other majors have proven the efficacy, demand, profitability, market, and the procedure is now health insurance supported in many cases.

Investor Q&A calls: Twice daily (10am & 4pm PST) Monday-Friday/Robert > Call 1-727-731-5165

Products & Services

Sierra Ligation System

Development based on IP Licensed from 3 Cardiologists at Mayo Clinic. Worked in close partnership with a leading American academic medical clinic and Biomerics LLC partners to develop a (patent protected) engineered device that can deliver a simpler, cheaper and safer percutaneous epicardial procedure for left atrial appendage (LAA) closure. The “Sierra” is one of the only “single access” epicardial (LAA) closure devices and procedures known to be in development; • Patented electrocardiogram (ECG) navigation for less invasive and more accurate closure • Patented hollow structure ligation • One size fits all economics • Repositionable design • Elimination of Heparin or post procedure oral anticoagulation (OAC) Features: 1. Single access, no need to enter circulation or manage two access points. 2. Shortest implant times 3. Safety, no device left in LAA 4. Efficacy: Reduce stroke, hypertension & potential - reductions in BP. Better closure rates of LAA to prevent clots.

Team

A

Amber S

VICE PRESIDENT ADVISOR

VICE PRESIDENT, REGULATORY COMPLIANCE AND CORPORATE SECRETARY • More than 25 years of public company experience including corporate affairs, legal and...

Stay in the Loop

Get updates from Aegis Medical Innovations

Get exclusive updates from Aegis Medical Innovations

Be the first to know about company milestones, news, and opportunities.

🔒 No spam. Just real progress.

Company Stats

Key metrics about Aegis Medical Innovations

Industry MEDICAL DEVICES & EQUIPMENT

Fuel Level

Engagement metrics for Aegis Medical Innovations

0
Fuel Points

Fuel represents engagement and interest in this company from the Crowdigy community.

Are you the owner of Aegis Medical Innovations?

Claim your company profile to respond to reviews, update your information, and connect with investors.

Claim This Company

Disclosures

crowdigy.com is a website owned by Crowdigy LLC. Crowdigy LLC. operates sections of crowdigy.com where certain Regulation Crowdfunding, Regulation D and Regulation A+ offerings are available. Crowdigy LLC. is not regulated in any capacity, is not registered as either a broker-dealer or funding portal, and is not a member of FINRA or any other self-regulatory organization.

In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and the risks involved. Investing in companies is a highly risky activity, which may include a risk or loss capital. Crowdigy LLC is not making any guarantees. If investors lose all or part of their investments, the investors will not have a right to recover from Crowdigy LLC except only to the extent Crowdigy LLC is determined to be liable under current securities laws.

Information displayed by crowdigy.com that is not controlled or accessed by registered investors or companies features information publicly available through open internet platforms or publicly released information or data sources.

Anyone with a financial stake in a company in a fundraising capacity, such as a promoter, employee, or founder, must disclose their relationship when communicating with other investors. Investors should read our educational materials on startup investing. Educational materials are continually updated at https://crowdigy.com/investors.

By using crowdigy.com, you accept our Terms and Conditions & Privacy Policy. If investing, you accept our Investor Agreement. You may also view our Privacy Notice.

This is an electronic platform where business owners can be featured to raise money from investors in return for securities or other arrangements, and where investors can browse opportunities to invest. Opportunities or securities presented on this site have not been registered, recommended or approved by any federal or state securities commission, regulatory authority or Crowdigy LLC.

All the information on this site is provided by the issuers or publicly available information and any investments or investment details are facilitated by their funding portal.

All representations of information is not validated or certified by Crowdigy LLC and is the responsibility of the information providers or respective companies that control their own profiles or cards. By using Crowdigy you agree and understand Crowdigy is NOT a licensed broker-dealer and does not provide any investment advice or recommendation and does not provide any legal or tax advice with respect to any securities or offers. Any features, placements or promotions of opportunities on Crowdigy should not be construed as an endorsement or recommendation.

We use cookies on this site to enhance your user experience and analyze site traffic. By clicking "Accept", you consent to our use of cookies. Learn more